Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

@article{McKeage2008TrastuzumabAP,
  title={Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.},
  author={Kate McKeage and Katherine A Lyseng-Williamson},
  journal={PharmacoEconomics},
  year={2008},
  volume={26 8},
  pages={699-719}
}
Trastuzumab (Herceptin) is a monoclonal antibody approved for the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2). Well designed clinical trials in women with early breast cancer have demonstrated that 1 years' therapy with adjuvant intravenous trastuzumab (a loading dose followed by 6 mg/kg every 3 weeks or 2 mg/kg weekly) significantly improves disease-free survival and overall survival compared with observation (subsequent to chemotherapy) or… CONTINUE READING